Cancer · Austria
Myeloproliferative neoplasms
How is it diagnosed today? Polycythaemia vera mostly starts later in life: the average age at diagnosis is 60. NCI PDQ
What do you need help with?
- Join a trialStudies open to new patients in your country, and abroad if you want.10 open trials in Austria
- Offer tissue or dataGive a sample or your health data to research.
- Get supportPatient groups, money and work, help for family.
- Access and costGetting a treatment that is not on offer here, and who pays.
- Questions for your doctorReady lists to print or copy before your next visit.
- Don't pay for thisOffers with no proof in people, and what to check first.
Where treatment stands
Four steps, from proven to unproven.
Approved in Austria
Usual treatment: Venesection, low-dose aspirin, hydroxyurea. NCI PDQ
We do not have the list of medicines approved in Austria yet. Your doctor knows what is available here.
Being tested in people
10 open trials in Austria, 184 worldwide. See the trials
- 81-mg aspirin once daily (Phase 3)
- 81-mg aspirin twice daily (Phase 3)
- ACE-536 (Phase 3)
- Anagrelide (Phase 3)
Only in the lab or in animals
Not counted yet for this disease.
No proof it works
Animal worm medicines (ivermectin, fenbendazole) for cancer: not approved, and not enough research in people to know if they help. American Cancer Society: What to Know About Ivermectin (21 May 2026) · American Cancer Society: What to Know About Fenbendazole (21 Oct 2025)
Join a trial
Studies that are taking new patients in Austria. The trial team decides who can join. Change the country at the top.
Phase 1: first tests in people · Phase 2: does it help? · Phase 3: compared with the usual treatment
10 open trials in Austria
Tests pelabresib with ruxolitinib in adults with myelofibrosis
NCT07357727 · ClinicalTrials.gov
- Graz – Medical University of Graz
- Salzburg – Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbH
- Vienna – Hanusch Krankenhaus der Wiener Gebietskrankenkasse
Age 18 and over
Contact the trial teamLong-term asciminib treatment for people with chronic myeloid leukemia
NCT04877522 · ClinicalTrials.gov
- Graz – Medical University of Graz
- Linz – Ordensklinikum Linz GmbH
- Vienna – Hanusch Krankenhaus der Wiener Gebietskrankenkasse
Ages 7 to 100
Contact the trial teamTests elritercept against placebo for anemia in myelofibrosis
NCT07623161 · ClinicalTrials.gov
- Innsbruck – Medizinische Universitaet Innsbruck
- Linz – Ordensklinikum Linz GmbH
- Vienna – Medical University of Vienna
- and 1 more site
Age 18 and over
Contact the trial teamTests INCA033989 Against Standard Care in Essential Thrombocythemia
NCT07623200 · ClinicalTrials.gov
- Graz – LKH - Medizinische Universitaet Graz
- Leoben – Landeskrankenhaus (Lkh) Leoben - Standort Leoben
- Linz – Ordensklinikum Linz GmbH Elisabethinen
- and 2 more sites
Age 18 and over
Contact the trial teamTests sapablursen with standard care in polycythemia vera
NCT07429266 · ClinicalTrials.gov
- Graz – Medical University of Graz
- Innsbruck – Medizinische Universitaet Innsbruck
- Linz – Ordensklinikum Linz GmbH
- and 2 more sites
Age 18 and over
Contact the trial teamTests oral nuvisertib in people with myelofibrosis
NCT04176198 · ClinicalTrials.gov
- Graz – Medical University of Graz
Age 18 and over
Contact the trial teamTests bezuclastinib in adults with advanced systemic mastocytosis
NCT04996875 · ClinicalTrials.gov
- Vienna – AKH Wien, Universitatsklinikum
Age 18 and over
Contact the trial teamTesting Navtemadlin Added to Ruxolitinib for Myelofibrosis Patients
2023-504724-25-00 · EU Clinical Trials Register
- Graz – Medical University of Graz
- Innsbruck – Medizinische Universitaet Innsbruck
- Linz – Johannes Kepler University Linz
- and 2 more sites
Age 18 and over
Contact the trial teamCompares givinostat with hydroxyurea in high-risk polycythemia vera
NCT06093672 · ClinicalTrials.gov
- Linz – Ordensklinikum Linz GmbH
- Vienna – Medical University of Vienna
- Wels – Klinikum Wels-Grieskirchen GmbH
Age 18 and over
Contact the trial teamTests navtemadlin added to ruxolitinib in myelofibrosis patients with a weak response
NCT06479135 · ClinicalTrials.gov
- Graz – University Hospital Graz, Department of Internal Medicine
- Innsbruck – Medical University Innsbruck, Department of Internal Medicine V (Hematology and Oncology)
- Leoben – Regional Hospital Hochsteiermark - Leoben, Department of Internal Medicine, Department of Hematology and Oncology
- and 4 more sites
Age 18 and over
The registry has not updated this record for a long time. Ask the team whether it is still open.
Contact the trial team
How to get into an early trial
- A lab does not treat patients, so you cannot phone the lab to get a new treatment.
- Ask your doctor to look at phase 1 trials with you. These are the first tests in people.
- If one fits, your doctor sends a referral to the trial centre.
- The trial team checks whether you can join and decides.
Trial data: ClinicalTrials.gov, courtesy of the U.S. National Library of Medicine; it does not endorse this site. EU trials: EU Clinical Trials Information System (CTIS), European Medicines Agency. We show the registry records; the trial team has the last word on who can join.
Latest research
The five newest articles. The label comes from the PubMed index: whether it was tested in people, in animals or only in the lab.
- Not labelled yetCase Report: Real-world experience with pacritinib after prior ruxolitinib exposure in myelofibrosis in Saudi Arabia: a report of five cases.Front Med (Lausanne) · 2026-10-26
- In peopleHematological trajectories and pregnancy complications in essential thrombocythemia and polycythemia vera.Ann Hematol · 2026-08-13
- Not labelled yetEffects of calreticulin mutations on HLA class I expression in myeloproliferative neoplasms.JCI Insight · 2026-11-10
- Not labelled yetPortal and hepatic vein thrombosis in Philadelphia-negative myeloproliferative neoplasms: Insights from the National Inpatient Sample.Thromb Res · 2026-11-09
- ReviewSGLT2 Inhibitors and Hemoglobin Improvement in Myelodysplastic Syndromes and Myeloproliferative Neoplasms: Mechanistic Rationale and Emerging Clinical Evidence.Anemia · 2026-11-08
Not labelled yet: PubMed has not indexed the article yet, so we do not guess.
More research on the disease pageIs it true?
Saw something on social media? Fact-check it now.
Get screened
For family members and people at higher risk: free checks can find some cancers early, before there are symptoms.
There is no routine screening for this cancer. If you have symptoms or a family history, talk to your doctor.
If several people in your family had cancer, ask your GP whether genetic counselling makes sense for you.
Offer tissue or data
You can help research move faster.
Give tissue or blood to research
Before an operation or a blood test, ask if left-over tissue or blood can go to a biobank.
- Does this hospital have a biobank?
- What will the sample be used for, and for how long?
- Can I change my mind later?
Share your health data
Ask your doctor whether there is a patient registry for your illness. You choose what you share.
Take part as a healthy volunteer
Some studies need people without the illness, often family members.
Volunteer studiesGet support
Patient groups in Austria
- Österreichische Krebshilfe
Free, anonymous counselling at regional centres in every federal state, psycho-oncology and emergency financial aid.
Phone: 01 7966450
- MPN Austria
Austrian patient association for people with myeloproliferative neoplasms (MPN) and their relatives. Member of MPNAN.
Help for every illness in Austria (4)
- 1450 – Rund-um-die-Uhr-Gesundheitsberatung
Austria's nationwide 24/7 telephone health advice line: trained staff assess symptoms and guide callers to the appropriate care.
- Telefonseelsorge Österreich – Notruf 142
Free, confidential 24/7 emotional support and crisis line for anyone in Austria, reachable on 142.
- Gesundheitsportal Österreich (gesundheit.gv.at)
Austria's official public health portal, offering quality-assured information on diseases, prevention, health services and patient rights.
- ARGE Selbsthilfe Österreich
ARGE Selbsthilfe Österreich represents the interests of self-help groups and patient organisations in Austrian social and health policy.
Available abroad: international groups (6)
- European Cancer Patient Coalition (ECPC)
Umbrella of European cancer patient groups, with a patient toolbox and a legal network for cancer patients.
- EURORDIS – Rare Diseases Europe
Alliance of over 1,000 rare disease patient organisations, with a list of rare disease helplines by country.
- MPN Advocates Network
Global network of MPN patient groups: advocacy education, MPN Awareness Day, global patient survey, webinars, MPN Horizons conference.
- Workgroup of European Cancer Patient Advocacy Networks
Network of pan-European cancer patient umbrella groups (including the blood cancer networks): joint advocacy, WECAN Academy training for patient advocates, patient experience data courses.
- European Patients' Forum (EPF)
Umbrella of European patient organisations and national patient coalitions.
- International Alliance of Patients' Organizations
Global alliance of patient organisations of all diseases, promoting patient-centred healthcare.
Money and work
If the illness stops you working, ask the hospital social worker which benefits you can claim.
- Which sick-pay or disability benefits can I apply for?
- Is there help for the carer in the family?
- Are travel costs to treatment paid back?
After a loss
If someone you love has died, you do not have to go through it alone. Many families ask themselves whether they missed something; the care team can talk this through with you.
We have no grief support group in Austria in our list yet. The hospital's social worker or palliative team can tell you where to find one.
Hospitals and hospices have chaplains and counsellors, for any faith or none.
Some families decide to give tissue to research after death, so that the illness can be studied. If you want to, ask the treating hospital early whether it has such a programme.
Access and cost
- If no trial fits, your doctor can ask the company and the medicines authority whether early access (compassionate use) is possible.
- In Austria the medicines agency BASG lists the early-access programmes that are running. BASG (Austria): list of compassionate use programmes, no. 054
- In the EU you may get planned care in another EU country. Ask your health insurer before you go. Your Europe: planned medical treatment abroad
Don't pay for this
No one will cure you through a Facebook message or ask you to invest money.
- Animal worm medicines bought online (ivermectin, fenbendazole)
They are made for animals and not tested for cancer in people. High doses can cause seizures or coma, fenbendazole has caused liver damage, they may weaken your cancer treatment, and they can keep you out of a trial.
American Cancer Society: What to Know About Ivermectin (21 May 2026) · American Cancer Society: What to Know About Fenbendazole (21 Oct 2025) · ASCO: Oncologists urged to discuss ivermectin and fenbendazole (17 Jun 2026)
- “Treatment plans” offered in comments
Ask which published study in people is behind it. Usually there is none.
- Anyone who answers your post with a private treatment
Real trials are listed in a public registry. Check the number on ClinicalTrials.gov or the EU trial register.
- Strangers offering investments or “funds” for treatment
Do not reply and do not send money. Report the comment or message.
Before you pay for anything, ask three things
- Can I have a written price, with everything that is included?
- Which published study in people shows it helps my disease?
- What does my doctor say about it?
Questions for your doctor
Ready lists for a new diagnosis, during treatment, before a trial and before you pay. Open the question lists
Not medical advice. We show what is open and what is known; your care team decides what fits you.